Arca
Skip to content
Tools
Tools

SLC10A1: Hepatic sodium/bile acid cotransporter

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3

Who Is On It, and How Far Along

Every drug ChEMBL records acting on SLC10A1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide
  • Other

Approved1

  • Bulevirtide

Phase 30

    Phase 22

    • Hepalatide
    • Myrcludex b

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Bile acid transporter inhibitor.
      BulevirtideApprovedGilead SciencesProtein or peptideInhibitor—12—
      HepalatidePhase 2Shanghai HEP Pharmaceutical Co., Ltd.Protein or peptideInhibitor—1—
      Myrcludex bPhase 2Hepatera Ltd.OtherInhibitor—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.
      Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+DBulevirtide—RecruitingResearch Center of Periodontal-Systemic Interactions2026-03-25
      Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideBulevirtidePhase 2 / Phase 3RecruitingMirum Pharmaceuticals, Inc.2026-03-06
      Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With BulvertideBulevirtide—RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCS2026-02-24
      10119473 -VIROMARKERS HDV Biomarkers StudyBulevirtide—Not yet recruitingUniversity of Rome Tor Vergata2025-12-31
      Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis DHepalatidePhase 3Not yet recruitingShanghai HEP Pharmaceutical Co., Ltd.2025-12-30
      A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)BulevirtidePhase 3RecruitingMirum Pharmaceuticals, Inc.2025-10-01
      A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionBulevirtidePhase 2Active, not recruitingVir Biotechnology, Inc.2025-08-27
      A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideBulevirtidePhase 3Active, not recruitingVir Biotechnology, Inc.2025-08-19
      Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV InfectionBulevirtideNot applicableActive, not recruitingHannover Medical School2024-09-19

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Hypercholanemia, familial, 2
      0.71
      Hepatitis D virus infection
      0.48
      Viral infectious disease
      0.38
      Hypercholanemia, familial 1
      0.37
      Hypercholanemia, familial
      0.37
      Intrahepatic cholestasis of pregnancy
      0.20
      Self-injurious ideation
      0.19
      Hepatitis B virus infection
      0.14
      Chronic hepatitis B virus infection
      0.10
      Cirrhosis of liver
      0.08
      Infection
      0.06

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5287, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q14973, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.